Endo Announces Resolution of Government Investigation

            Endo Announces Resolution of Government Investigation

PR Newswire

MALVERN, Pa., Feb. 21, 2014

MALVERN, Pa., Feb. 21, 2014 /PRNewswire/ -- Endo Pharmaceuticals, a subsidiary
of Endo Health Solutions Inc. (Nasdaq: ENDP), announced today that it has
reached a resolution of criminal and civil claims with the federal and
participating state authorities and the District of Columbia regarding a
previously disclosed investigation concerning past US sales, marketing and
promotional practices related to Endo Pharmaceuticals Inc. product Lidoderm®.
Under the agreement, the company will pay a total of up to a previously
reserved $194 million.

As a part of the settlement, Endo has entered into a Deferred Prosecution
Agreement (DPA) with the United States Department of Justice (DOJ) for a
period of up to 2 ½ years and a Corporate Integrity Agreement (CIA) with the
United States Department of Health and Human Services, Office of Inspector
General (HHS-OIG) for a period of (5) years. The agreements build on Endo's
existing comprehensive compliance programs.

"The company takes its responsibility to patients, healthcare providers and
our shareholders very seriously," said Endo's president and chief executive
officer, Rajiv De Silva. "We are pleased to resolve this matter and are
confident that we have robust programs in place to assist us in satisfying our
legal and regulatory agreements. We are committed to a company culture that
supports the conduct of our business in a compliant and ethical manner." 

About Endo Pharmaceuticals Inc.

Endo Pharmaceuticals Inc., headquartered in Malvern, PA, is focused on
developing and delivering high-value branded pharmaceutical products that meet
the unmet needs of patients. The company is currently focused in the areas of
Pain Management, Urology, and Endocrinology. Endo Pharmaceuticals is an
operating company of Endo Health Solutions Inc. (NASDAQ: ENDP), a specialty
healthcare company with segments focused on branded pharmaceuticals, generics,
and medical devices, each providing quality products to customers intended to
improve the lives of patients. Learn more at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements including
words such as "believes," "expects," "anticipates," "intends," "estimates,"
"plan," "will," "may," "look forward," "intend," "guidance," "future" or
similar expressions are forward-looking statements. Because these statements
reflect our current views, expectations and beliefs concerning future events,
these forward-looking statements involve risks and uncertainties. Investors
should note that many factors, as more fully described under the caption "Risk
Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities
and Exchange Commission and as otherwise enumerated herein or therein, could
affect our future financial results and could cause our actual results to
differ materially from those expressed in forward-looking statements contained
in our Annual Report on Form 10-K. The forward-looking statements in this
press release are qualified by these risk factors. These are factors that,
individually or in the aggregate, could cause our actual results to differ
materially from expected and historical results. We assume no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future developments or otherwise.

SOURCE Endo Pharmaceuticals

Website: http://www.endo.com
Contact: Investors/Media: Blaine Davis, (484) 216-7158; Investors: Jonathan
Neely, (484) 216-6645; Media: Brian O'Donnell, (484) 216-6726
Press spacebar to pause and continue. Press esc to stop.